The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

29/05/2021

Antiviral Research

Volume 178, June 2020, 104787

Highlights

• Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro.

• A single treatment able to effect ~5000-fold reduction in virus at 48 h in cell culture.

• Ivermectin is FDA-approved for parasitic infections, and therefore has a potential for repurposing.

• Ivermectin is widely available, due to its inclusion on the WHO model list of essential medicines.